Vedanta Biosciences Announces $16.6 Million Series C-2 Financing
23 Septiembre 2019 - 1:00AM
Business Wire
New funding brings total Series C and C-2
capital raised to $62.1 million
Vedanta Biosciences, a clinical-stage company developing a new
category of therapies for immune-mediated diseases based on
rationally-defined consortia of human microbiome-derived bacteria,
today announced a $16.6 million Series C-2 financing round,
bringing the total capital raised in its Series C and C-2 round to
$62.1 million. Participants include QUAD Investment Management, SV
Investment Corp., Shinhan Investment-Private Equity, Shinhan
Capital-Yeollim Partners, Partners Investment Co., Ltd, FC Capital,
and SymBiosis LLC, who join the previously announced Series C
investors, including the Bill & Melinda Gates Foundation,
Bristol-Myers Squibb, Rock Springs Capital, JSR Corporation,
Shumway Capital, Invesco Asset Management, Health for Life
(Seventure Partners), and founder PureTech Health. The funding
further supports the expansion of Vedanta’s broad clinical
pipeline, including the recently launched Phase 1b/2 study of VE416
in food allergy, a planned Phase 1b/2 study of VE800 and OPDIVO®
(nivolumab) in advanced or metastatic cancers, and the ongoing
Phase 2 study of VE303 in recurrent Clostridioides difficile
infection (rCDI).
“We welcome the support from both existing and new investors for
Vedanta’s expanding activities and maturing portfolio of product
candidates based on rationally-defined consortia,” said Bernat
Olle, Ph.D., co-founder and chief executive officer of Vedanta
Biosciences.
Vedanta Biosciences is developing drug candidates based on
consortia of natural non-pathogenic bacterial strains designed to
effect robust and durable therapeutic changes in a person’s gut
microbiota. In contrast to fecal transplants or administration of
fecal fractions, Vedanta Biosciences' consortia are defined
compositions of bacteria manufactured from pure, clonal cell banks,
bypassing the need to rely on direct sourcing of fecal donor
material of inconsistent composition.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage microbiome leader
developing a new category of therapies for immune-mediated diseases
based on rationally-defined consortia of human microbiome-derived
bacteria. Vedanta’s proprietary capabilities include what is
believed to be the largest collection of human-gut associated
bacteria, assays and bioinformatics techniques for consortia design
and optimization, vast datasets from human interventional studies
and facilities for cGMP-compliant manufacturing of
rationally-defined bacterial consortia in powder form.
Vedanta Biosciences' pioneering work, in collaboration with its
scientific co-founders, has led to the identification of human
commensal bacteria that induce a range of immune responses –
including induction of regulatory T cells, CD8+ T cells, and Th17
cells, among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature (2013,
2019), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of investigational live biotherapeutic products
(LBPs) in infectious disease, autoimmune disease, allergy, and
immuno-oncology. This pipeline includes three clinical-stage
product candidates currently being evaluated for the treatment of
recurrent C. difficile infection and inflammatory bowel disease (in
collaboration with Janssen Biotech, Inc.), and food allergy, as
well as a fourth product candidate expected to enter the clinic in
2019 in patients with advanced or metastatic cancers (in
combination with Bristol-Myers Squibb’s checkpoint inhibitor
OPDIVO®).
Vedanta’s IP portfolio contains over 30 issued patents with
coverage extending to 2037. Vedanta Biosciences was founded by
PureTech Health (LSE:PRTC). Its scientific co-founders are
world-renowned experts in immunology and microbiology who have
pioneered the fields of innate immunity, Th17 and regulatory T cell
biology.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190922005062/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
US media Tom Donovan +1 857 559 3397
tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De May 2023 a May 2024